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Abstract. Melioidosis is caused by the saprophytic organism Burkholderia pseudomallei. The use of the indirect
hemagglutination assay (IHA) has found widespread use in areas endemic for this disease. Using this assay, we explored
the serologic profile of 275 patients with culture-confirmed melioidosis in the Northern Territory of Australia. Based on
a threshold titer of 1:40, the sensitivity of the IHA on admission was 56%. Female patients, those with positive blood
cultures, and those with pneumonia independently predicted a negative IHA result. Most patients (68%) with negative
admission IHA titers subsequently seroconverted. Most patients (92%) with positive admission IHA titers had persis-
tently positive IHA titers. Relapses were not observed in 36 patients who had a negative IHA at least 1 month after
admission, irrespective of initial admission IHA. The IHA has limited utility as a diagnostic test for acute disease, and
most patients subsequently have persistently positive titers after recovery from illness.
INTRODUCTION
Melioidosis, which is caused by the saprophytic gram-
negative bacillus Burkholderia pseudomallei, is endemic in
northern Australia and southeast Asia.1 Reported annual in-
cidence rates of this disease vary from 16.5 cases per 100,000
population in northern Australia2 to 4.4 per 100,000 in north-
eastern Thailand.3 It has protean presentations, may affect
almost any site in the body, and has a spectrum of severity
from acute fulminant sepsis to chronic infection. Risk factors
for disease include diabetes, heavy alcohol use, and chronic
renal disease.4 Diagnosis relies on positive culture; rapid di-
agnostic tests, particularly based on the detection of antibod-
ies, are confounded by the high prevalence of positive sero-
logic results in disease-endemic areas2,5–7
The immune mechanisms that mediate resistance to melioi-
dosis are poorly defined. Repeated natural exposure to B.
pseudomallei and antigenically related saprophytic organisms
are sufficient to induce specific antibodies. Although some
studies have suggested that high levels of specific antibodies
may be protective,8,9 specific antibodies in most patients are
insufficient to prevent or clear infection with B. pseudomallei.
Other work has demonstrated that a specific cell-mediated
response is present in survivors of melioidosis,10 but the lack
of association of melioidosis with infection with human im-
munodeficiency virus suggests that other mechanisms may
mediate protection against B. pseudomallei.
The indirect hemagglutination assay (IHA) remains the
only widely used serologic test for melioidosis, despite its
known poor sensitivity and specificity.7,11–14 In this study, we
explore the serologic profile of patients with culture-
confirmed melioidosis in northern Australia.
METHODS
Data on patients presenting to the Royal Darwin Hospital
since October 1989 have been collected prospectively in the
Darwin Prospective Study. The catchment area of the hospi-
tal incorporates the Top End region of the Northern Terri-
tory, encompassing an area of more than 500,000 km2 and
approximately 150,000 people. The data collected include
clinical and demographic data, as well as the results of inves-
tigations and follow-up data.
The IHA was conducted as previously described15,16 using
antigen produced from a combination of three clinical isolates
of B. pseudomallei previously isolated from different geo-
graphic regions in the Top End of the Northern Territory. A
negative serologic result was defined as an IHA titer  1:20,
low positive as 1:40 or 1:80, high positive as between 1:160 and
1:1,280 inclusive, and very high positive as > 1:1,280. Patient
serum for testing was heat inactivated at 56°C and treated
with unsensitized ovine erythrocytes. After centrifugation,
the supernatant was then serially titrated and reacted with
ovine erythrocytes sensitized to B. pseudomallei antigen. Un-
sensitized ovine erythrocytes were used as a control.
We defined admission serologic results as the IHA titer
obtained within three days of admission to a hospital. Relapse
was defined as the recurrence of the clinical features of
melioidosis after apparent cure from a previous episode of
melioidosis with appropriate antibiotic therapy. Previous
local work has defined relapse to be due to the same strain
in 93% of the cases.17 Chronic disease was defined as occur-
ring in patients with more than two months of symptoms.17
Severe sepsis was defined according to established criteria
that include the presence of sepsis and end-organ dysfunc-
tion.18
We identified four patterns of serologic change in patients
with melioidosis; those with negative IHA titers on admission
but who subsequently seroconverted (seroconversion), those
with positive IHA titers on admission but whose IHA titer
waned to negative subsequently (seroreversion), those with
persistently negative IHA titers, and those with persistently
positive titers. We specifically considered IHA in three clini-
cally distinct groups of interest: patients with chronic melioi-
dosis, patients with later relapsed disease and patients with
severe melioidosis (indicated by the presence of bacteremia
and/or severe sepsis).
Proportions across ordered groups were compared using
Cuzick’s non-parametric test for trend. Proportions across
non-ordered groups were compared using the Fisher’s exact
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test. Geometric means of IHA titers of groups were com-
pared using the log rank test. Multivariate models were con-
structed using backward stepwise selection examining clinical
factors that predicted IHA titer. The IHA titers were consid-
ered both in ordered categories (negative, low positive, posi-
tive, and highly positive) and as a dichotomous variable (posi-
tive or negative). Post-regression diagnostic plots were con-
structed to discount the effect of statistical outliers. Statistical
tests were performed using Intercooled Stata version 8.2
(Stata Corporation, College Station, TX). Ethical approval
for this review was obtained from the Human Research Eth-
ics Committee of the Menzies School of Health Research and
the Department of Health and Community Services.
RESULTS
During the period from October 1989 to September 2002,
344 patients presented with culture-confirmed melioidosis. Of
these patients, the results of IHA on admission were available
for 275 patients and were included in this study. Of these
patients, 201 (73%) patients had IHA titers determined at
least one month subsequent to admission and were included
in the longitudinal analysis.
Of the 275 patients in this study, the median age at first
admission was 49 years (including 12 pediatric patients < 18
years of age) and 203 (74%) were male. Sites of infection
were similar to that previous described4 and included 140
(51%) patients with pneumonia, 42 (15%) with genitourinary
disease, 34 (12%) with sepsis without a clinical focus, 39
(14%) with infections involving skin or soft tissue, 11 (4.0%)
with encephalomyelitis or central nervous system infection,
and 9 (3.2%) involving other sites. Risk factors included dia-
betes in 107 patients (39%), alcoholism in 97 patients (35%)
and chronic renal disease in 24 patients (8.7%). Severe sepsis
was present on first admission in 56 (21%) of the 272 patients
where this was recorded and bacteremia in 135 (51%) pa-
tients of the 273 patients where blood cultures were per-
formed. A chronic presentation was noted in 32 (12%) pa-
tients. Culture-confirmed relapse was seen in 27 patients. The
overall mortality was 14% (n  38).
Admission IHA titers. A significant proportion of patients
had negative IHA titers (44%, n 120) on admission. Of the
155 patients (56%) with positive serologic results, 42 (27%)
had low positive titers, 77 (50%) had high positive titers, and
36 (23%) had very high positive titers. Clinical characteristics
and admission IHA titers are shown in Table 1. The sensitiv-
ity of the IHA was 56% at a threshold titer of 1:40 and 41%
at a threshold titer of 1:160. Of the 32 patients with chronic
presentations of melioidosis, the sensitivity of the IHA was
81% and it was higher than in patients with acute presenta-
tions (53%; P  0.002, by Fisher’s exact test).
Univariate analysis showed that female sex, pneumonia,
acute presentation, positive blood cultures, and chronic renal
disease predicted a negative IHA titer. Multivariate analysis
showed that female sex, pneumonia, and positive blood cul-
tures were independently predictive of negative IHA titers.
TABLE 1
Clinical factors and admission indirect hemagglutination assay titer in 275 patients
Variable No. of patients Negative Low positive High positive Very high positive Significance* P Adjusted coefficient† Significance P
All patients 275 120 (44%) 42 (15%) 77 (28%) 36 (13%)
Age, years
< 49 135 55 (41%) 17 (13%) 40 (30%) 23 (17%) 0.08
> 49 140 65 (46%) 25 (18%) 37 (26%) 13 (9.3%)
Sex
Male 203 78 (38%) 33 (16%) 62 (31%) 30 (15%) 0.004 −0.34 0.02
Female 72 42 (58%) 9 (13%) 15 (21%) 6 (8.3%)
Ethnicity
Aboriginal 147 70 (48%) 21 (14%) 39 (27%) 17 (12%) 0.16
Non-aboriginal 128 50 (39%) 21 (16%) 38 (30%) 19 (15%)
Diabetes
Present 107 51 (48%) 16 (15%) 30 (28%) 10 (9.4%) 0.18
Absent 168 69 (41%) 26 (15%) 47 (28%) 26 (15%)
Heavy alcohol intake
Present 97 43 (44%) 13 (13%) 31 (32%) 10 (10%) 0.82
Absent 178 77 (43%) 29 (16%) 46 (26%) 26 (15%)
Chronic renal failure
Present 24 16 (67%) 1 (4.2%) 5 (21%) 2 (8.3%) 0.052
Absent 251 104 (41%) 41 (16%) 72 (29%) 34 (14%)
Pneumonia
Present 140 78 (56%) 17 (12%) 32 (23%) 13 (9.3%) < 0.001 −0.42 0.001
Absent 135 42 (31%) 25 (19%) 45 (33%) 23 (17%)
Presentation
Acute 243 114 (47%) 36 (15%) 65 (27%) 28 (12%) 0.001 −0.44 0.035
Chronic 32 6 (19%) 6 (19%) 12 (38%) 8 (25%)
Severe sepsis‡
Present 56 30 (54%) 4 (7.1%) 15 (27%) 7 (13%) 0.32
Absent 216 89 (41%) 38 (18%) 62 (29%) 27 (13%)
Blood cultures‡
Positive 138 78 (57%) 17 (12%) 30 (22%) 13 (9.4%) < 0.001 −0.41 0.002
Negative 135 40 (30%) 25 (19%) 25 (19%) 23 (17%)
* Proportions across ordered groups were compared using Cuzick’s non-parametric test for trend.
† Final model was selected by backward stepwise selection; candidate independent factors were selected using P < 0.2.
‡ Presence of severe sepsis was not documented in three patients; blood cultures were not performed in two patients.
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Table 1 lists factors associated with a higher category of IHA
titer; with the exception of chronic renal failure (univariate P
 0.053) and acute presentation (multivariate P  0.10),
these factors were similar to those associated with a positive
titer. The multivariate model was robust on exclusion of 11
outliers identified by a leverage versus squared residual plot,
but only accounted for 14% of the variation in admission IHA
titer category observed (r2).
The distribution of IHA titers was not significantly differ-
ent in the 38 patients that died of melioidosis, with 22 (58%)
having negative admission titers, 3 (7.9%) low positive titers,
9 (24%) high positive titers, and 4 (11%) very high titers
(P  0.13, by non-parametric test for trend compared with
survivors). A higher proportion of patients that died had
negative admission IHA titers but this was not statistically
significant (58% versus 41%; P  0.078, by Fisher’s exact
test).
Longitudinal IHA titers. Of the 275 patients in this study,
201 had subsequent IHA titers at least one month after ad-
mission and were further analyzed. Of the 82 patients with
initial negative IHA titers, 56 (68%) seroconverted and 26
(32%) remained persistently negative by IHA. Of the 119
patients with initial positive IHA titer, 10 (8%) had subse-
quent negative IHA titers and 109 (92%) remained persis-
tently positive. Details of patterns of serologic changes and
clinical factors are shown in Table 2.
Patients with chronic disease had persistently positive IHA
titers in 84% of the cases, a pattern only observed in 50% of
the 176 patients with acute presentations where a subsequent
IHA was conducted. Patients with positive blood cultures had
a seroconversion pattern in 41% of cases where a repeat IHA
was available (a pattern observed in 17% of patients that
were blood culture negative). In contrast, persistently positive
IHA titers were observed in 67% of patients with negative
cultures where repeat IHA results were available compared
with 40% of blood culture–positive cases. There were no
other significant correlations observed between clinical fea-
tures and patterns of serologic changes.
Relapsed disease. Of the 275 patients in this study, 27
(10%) patients had 33 episodes of relapse (including six
with two episodes of relapse). First relapses occurred a
median of 27 weeks after the first presentation (interquar-
tile range [IQR]  13–36 weeks) and second relapses
occurred a median of 87 weeks after first presentation
(IQR  6–115 weeks). Admission titers on relapse were
available in 29 (87%) of 33 episodes; 4 patients had negative
IHA titers, 6 patients had low positive titers, 10 patients had
high positive titers, and 9 patients had very high positive ti-
ters.
Of the 27 patients with relapse, 19 had IHA titers deter-
mined between first and second episodes. A seroconversion
pattern occurred after the first presentation in 5 patients (rep-
resenting 9% of the 56 patients where this pattern was ob-
served), and a persistently positive pattern was observed in 14
patients (13% of the 109 patients who had persistently posi-
tive serologic results). None of the 36 patients with negative
TABLE 2











All patients 201 56 (28%) 26 (13%) 10 (5%) 109 (54%)
Age, years
< 47 95 24 (25%) 11 (12%) 4 (4%) 56 (59%) 0.63
> 47 109 32 (30%) 15 (14%) 6 (6%) 53 (50%)
Sex
Male 156 41 (26%) 19 (12%) 7 (4%) 89 (57%) 0.44
Female 45 15 (33%) 7 (16%) 3 (7%) 20 (44%)
Ethnicity
Aboriginal 101 33 (33%) 13 (13%) 5 (5%) 50 (50%) 0.46
Non-aboriginal 100 23 (23%) 13 (13%) 5 (5%) 59 (59%)
Diabetes
Present 82 26 (32%) 10 (12%) 3 (4%) 43 (52%) 0.73
Absent 119 30 (25%) 16 (13%) 7 (6%) 66 (55%)
Heavy alcohol intake
Present 73 25 (34%) 7 (10%) 2 (3%) 39 (53%) 0.31
Absent 128 31 (24%) 19 (15%) 8 (6%) 70 (54%)
Chronic renal failure
Present 14 5 (26%) 4 (29%) 1 (7%) 4 (29%) 0.10
Absent 187 51 (27%) 22 (12%) 9 (5%) 105 (56%)
Pneumonia
Present 96 37 (39%) 13 (14%) 6 (6%) 42 (43%) 0.008
Absent 105 19 (18%) 13 (12%) 4 (4%) 67 (64%)
Presentation
Acute 176 55 (31%) 23 (13%) 10 (6%) 88 (50%) 0.004
Chronic 25 1 (4%) 3 (12%) 0 21 (84%)
Severe sepsis†
Present 179 10 (48%) 2 (10%) 1 (5%) 8 (38%) 0.22
Absent 21 46 (25%) 24 (13%) 9 (5%) 100 (56%)
Blood cultures†
Positive 92 38 (41%) 14 (15%) 3 (3%) 37 (40%) < 0.001
Negative 108 18 (17%) 11 (10%) 7 (6%) 72 (67%)
* Proportions across non-ordered groups were compared using the Fishers’s exact test.
† Presence of severe sepsis was not documented in one patient; blood cultures were not performed in one patient.
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interval IHA titers relapsed, irrespective of their admission
IHA titer. Three patients with relapse had persistent titers >
1:1,280 (a pattern observed in 9 patients in this study) and one
additional patient had a titer > 1:1,280 after a negative titer on
first admission.
DISCUSSION
The IHA is a cheap and simple test that is the only sero-
logic test with widespread use in the diagnosis of melioidosis
in disease-endemic countries. It has remained essentially un-
changed since it was first described in 1965.19 However, pre-
vious studies have demonstrated a poor specificity due to a
high background rate of positive test results in disease-
endemic populations, as well as poor sensitivity.7,11–14 Our
study suggests that the sensitivity of admission IHA and the
subsequent patterns of change vary with the characteristics of
melioidosis. Whether acute disease is the result of a poor
humoral response or occurs prior to an effective response is
not clear.
We classified IHA by criteria in common use; in Australia,
a titer of 1:40 is considered positive,5 and in Thailand, a titer
of 1:160 is considered positive.20 In Queensland, Australia,
Ashdown and Guard reported that the background rate of
seropositivity in Australian patients based on the complement
fixation test was lower than in southeast Asian patients.5 In
two recent studies, the rate of positive serologic results in
controls without melioidosis was 8.7% (based on a threshold
IHA titer of 1:40), but in Thailand a rate of 35% was observed
(based on a higher IHA titer of 1:160).7,14 The reason for this
difference is not clear, but recent work has suggested that this
is not due to cross-reactivity to the antigenically related B.
thailandensis.21 We speculate that this represents a high ex-
posure to B. pseudomallei in the Thai population.
A limitation of the IHA is the variation in the strains used
(typically a combination of local clinical strains) and the un-
characterized nature of the antigenic epitopes and antibodies
involved. Based on fractionation of the antibodies detected in
positive IHA sera in 14 patients, Ashdown suggested that the
IHA reflected the IgM levels.22 With the lack of cross-
reactivity to B. thailandensis, it appears that lipopolysaccha-
ride (conserved between the species) is not the major anti-
genic epitope in the IHA, but rather that other antigens, such
as capsular polysaccharide, are more important in this assay.21
Whether strain variation between Thailand and Australia is
an important determinant of IHA titer has not been explored.
Studies using more sophisticated assays have defined that a
broad humoral response, involving all classes of immunglobu-
lins, is present in melioidosis, but the reasons for the poor
efficiency of these antibodies in preventing or clearing B.
pseudomallei is not known.23
Few studies have examined the pattern of serologic change
after an episode of melioidosis; in seven patients, a decrease
in the IgG level (detected by enzyme-linked immunosorbent
assay) appeared to correlate with successful treatment, but
only one patient in that study had a culture-confirmed re-
lapse.24 In our study, the most common pattern of serologic
change was persistently positive IHA titers after a positive
admission IHA.
Although we are not able to determine the longer term
significance of positive titers, few patients with persistently
positive titers were observed to relapse during the study pe-
riod, suggesting that persisting positive serologic results does
not necessarily mean persisting presence of infection. Latent
infection with subsequent disease has been described for pe-
riods of up to 62 years after presumed exposure.25 Positive
IHA results may not necessarily represent latent infection.
Although it was estimated that up to 225,000 returned U.S.
servicemen had positive serologic resulting after the Vietnam
War,26 the feared Vietnamese time bomb failed to material-
ize.27 In this study, one-third of the patients with persistent
titers > 1:1,280 were observed to relapse, although the small
numbers precluded definite conclusions. Although we did not
systematically examine pre-admission IHA titers, long-term
follow-up of patients with high IHA titers but no initial evi-
dence of disease at our center does occasionally unmask sub-
sequent melioidosis caused by reactivation from a presumed
latent focus.28 Conversely, it was observed that patients with
negative post-admission IHA titers (either after initial posi-
tive or negative IHA titers on first admission) did not subse-
quently relapse.
The IHA and other serologic tests lack both sensitivity and
specificity. More work is required to identify patients with
melioidosis early in the course of illness and to confirm our
observation that patients with a negative IHA result after
treatment have a low rate of relapse.
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